Automating Pediatric Cardiology GLP-1 Prior Auth Workflows

The Rise of GLP-1s in Pediatric Cardiology and PA Complexity

The use of GLP-1 receptor agonists is expanding, including for pediatric patients with type 2 diabetes or obesity-related comorbidities, often observed in conjunction with congenital heart conditions. This introduces significant prior authorization challenges, particularly given the high cost and strict payer criteria for these specialty pharmacologic interventions. The volume of GLP-1 prior authorizations has become a meaningful share of pharmacy-benefit PA transactions, as tracked by the CAQH Index.

Key Prior Authorization Triggers for GLP-1s in Pediatric Cardiology

• Prescription of high-cost GLP-1 receptor agonists (e.g., Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda).
• Indication for obesity where payer coverage varies significantly or is restricted.
• Requirement for step therapy documentation, often involving trials of metformin or other agents.
• Detailed clinical documentation of BMI, A1C, and relevant comorbidities for medical necessity.
• Coordination with advanced imaging like echocardiography or cardiac MRI, which also require prior authorization, for a holistic patient view.

Klivira's Indication-Aware GLP-1 Prior Auth Workflow

Klivira's platform automates the complex GLP-1 prior authorization process, starting with indication classification to differentiate between T2D and obesity. Our policy engine maintains per-payer obesity benefit status, routing requests based on whether the medication is covered, restricted, or not covered. We automate step therapy documentation by pulling metformin trial history, BMI, and comorbidity status directly from EMR data via FHIR, aligning with clinical guidelines such as the ADA Standards of Care for T2D treatment algorithms.

Seamless EMR Integration for Pediatric Cardiology Workflows

Klivira integrates directly with your EMR system using SMART on FHIR, enabling automated data extraction for GLP-1 prior authorizations. This includes pulling relevant clinical notes, lab results (A1C), and patient demographics, reducing manual data entry. Our system facilitates two-way communication, submitting PA requests via channels like X12 278 and NCPDP SCRIPT, and pushing status updates directly back into the EMR, streamlining the entire workflow for pediatric cardiology teams.

Optimizing Patient Access and Revenue Cycle Management

• **Brand-Specific Logic**: Applies distinct PA criteria for different GLP-1 products, ensuring accurate submissions.
• **Specialty Pharmacy Fulfillment**: Post-approval routing to specialty pharmacies for many GLP-1 products.
• **Denial Reduction**: Proactive identification of documentation gaps and adherence to payer-specific rules minimizes denials.
• **Patient Financial Counseling**: For non-covered obesity indications, Klivira can surface manufacturer copay programs and alternative coverage paths, enhancing patient support.

Compliance Considerations for Pediatric GLP-1 Prior Authorizations

Automating GLP-1 prior authorizations involves handling sensitive ePHI. Klivira's platform is designed with robust security protocols to protect patient data in accordance with HIPAA. Organizations should discuss their specific implementation and data handling practices with their compliance teams to ensure adherence to all relevant regulations, including those pertaining to CMS-0057-F and Da Vinci PAS recommendations for electronic prior authorization.